Abstract:Allo-HSCT is a potentially curative therapy for many hematological malignancies, the basis of which is graft-versus-leukemia (GVL) effect. However, acute graft-versus-host disease (GVHD) is responsible for 15% to 40% of mortality and is the major cause of morbidity after transplantation. Therefore, separation of GVHD and GVL partially or completely could improve the transplant outcomes. This study focuses on the effects of G-CSF on T cells in peripheral blood stem cell grafts and bone marrow grafts and its mechanisms after in vivo G-CSF application. The separation of GVHD and GVL effect and the mechanisms of which after in vivo G-CSF and interleukin-11 (IL-11) treatment of healthy donors were investigated. The main contributions of this research are listed as follows: (1) Immune tolerance of T cells was induced simultaneously in peripheral blood stem cell grafts and bone marrow grafts after in vivo G-CSF application; (2) T cell hyporesponsiveness and polarization of T cells from Th1 to Th2 were maintained after mixture of G-CSF-mobilized peripheral blood grafts (G-PB) and G-CSF-primed bone marrow grafts (G-BM) according to different proportions in vitro; (3) Treating donor with G-CSF and IL-11 decreased GVHD and retained GVL effect; (4) The incidence of acute GVHD was decreased after Allo-HSCT using G-PB and G-BM as allografts; (5) In combination with other techniques, the HLA barriers were overcomed using G-PB and G-BM as allografts; (6) The incidences of acute GVHD were significantly decreased and the GVL effects were retained or enhanced in relapsed patients after treatment by G-CSF-mobilized peripheral blood graft infusion compared with those received steady-state peripheral blood lymphocyte infusion, indicating that GVHD and GVL could be partially separated in clinical settings. Based on our results, we would conclude that the issues on the deficiency of donors are resolved, and novel strategies offered for the prophylaxis and treatment of patients with hematological malignancies who relapse after Allo-HSCT. Further studies on the mechanism of the separation of GVL and GVHD are warranted.

ren can zao zuo rg3 cu jin zi ti wai zhou xue gan xi bao yi zhi hou mian yi zhong jian de lin chuang guan cha

An Efficient Combination Immunotherapy for Antitumor Immunity Without Accelerating Cardiac Allograft Rejection.

Etiology, diagnosis, and treatment of post-transplant lymphoproliferative disorders]

Successful treatment of post-transplant lymphoproliferative disorder in allogeneic hemopoietic stem cell transplant recipient for severe aplastic anemia

Umbilical Cord Blood Transplantation From Unrelated Donors in Adult Patients with Hematological Malignancies

Retrospect and prospect of hematopoietic stem cell transplantation

Nonmyeloablative Allogeneic Hematopoietic Stem-Cell Transplantation a New Immunotherapy for Solid Tumor

Single-cell dissection of human hematopoietic reconstitution after allogeneic hematopoietic stem cell transplantation

Prevention and treatment of early transplantation-related complications after hematopoietic stem cell transplantation

Hematopoietic stem cell transplantation:everyone has a donor

Optimization of T-cell Replete Haploidentical Hematopoietic Stem Cell Transplantation: the Chinese Experience

[Therapeutic Effect of Allogeneic Hematopoietic Stem Cell Transplantation with Reduced-Intensity Conditioning Regimens on Hematological Malignancies].

Relapsing Hematologic Malignancies after Haploidentical Hematopoietic Stem Cell Transplantation

Hematopoietic blood stem cell transplantation

Donor-Derived CD19-Targeted T Cell Infusion Eliminates B Cell Acute Lymphoblastic Leukemia Minimal Residual Disease with No Response to Donor Lymphocytes after Allogeneic Hematopoietic Stem Cell Transplantation

[A Preliminary Study on the Treatment of Severe Autoimmune Disease by Autologous Peripheral CD(34)(+) Cell Transplantation].

Reconstitution of the Immune System after Hematopaetic Stem Cell Transplantation

Immune Reconstitution after Haploidentical Hematopoietic Stem Cell Transplantation.

Hematopoietic Stem Cell Transplantation with Fractionated Total Body Irradiation Based Preparation Regimen in Patients with Malignant Hematologic Diseases

Individualized immunotherapy based on blood cell chimerism after allogeneic hematopoietic stem cell transplantation

Immune Tolerance Induced by Cytokines in Allogeneic Hematopoietic Stem Cell Transplantation